Journal
CHEMICAL SCIENCE
Volume 11, Issue 39, Pages 10835-10843Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/d0sc01204a
Keywords
-
Categories
Funding
- European Union [801464, LP-03]
- Spanish Ramon y Cajal Programme [2014-16823]
- National Council of Science and Technology (CONACyT, Mexico) [CVU 419210]
- Austrian Agency for International Cooperation in Education and Research (OeAD-GmbH)
- CERIC-ERIC Consortium
- ARC [DP170103531]
- Australian Nanotechnology Network (ANN)
Ask authors/readers for more resources
Glycosaminoglycans (GAGs) are biomacromolecules necessary for the regulation of different biological functions. In medicine, GAGs are important commercial therapeutics widely used for the treatment of thrombosis, inflammation, osteoarthritis and wound healing. However, protocols for the encapsulation of GAGs in MOFs carriers are not yet available. Here, we successfully encapsulated GAG-based clinical drugs (heparin, hyaluronic acid, chondroitin sulfate, dermatan sulfate) and two new biotherapeutics in preclinical stage (GM-1111 and HepSYL proteoglycan) in three different pH-responsive metal-azolate frameworks (ZIF-8, ZIF-90, and MAF-7). The resultant GAG@MOF biocomposites present significant differences in terms of crystallinity, particle size, and spatial distribution of the cargo, which influences the drug-release kinetics upon applying an acidic stimulus. For a selected system, heparin@MOF, the released therapeutic retained its antithrombotic activity while the MOF shell effectively protects the drug from heparin lyase. By using different MOF shells, the present approach enables the preparation of GAG-based biocomposites with tunable properties such as encapsulation efficiency, protection and release.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available